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Who is it for? People who commission and plan the strategic 
response to drug misuse. this includes service commissioners, 
members of joint commissioning groups, and those working in 
local drug partnerships, primary care trusts and other local public 
health services. service providers may find it useful in considering 
their own investigative processes into drug-related deaths.
What is it about? the document contains ideas and examples 
of local practice in investigating and reviewing the causes of 
drug-related deaths. all are drawn from existing local systems in 
England. the document also takes partnerships through the chain 
of decisions they will want to consider in setting up their own 
review processes within their existing organisational frameworks.  
 
Partnerships may find it useful to have review processes to 
investigate, and learn lessons from, drug-related deaths. this 
document can help by offering real-world examples and advice on 
what to consider. however the advice in this document does not 
promote one system as better than another, and what works well 
for some local areas may not work as well in others.  
Methodology: the material in this report is drawn from 
interviews with 14 local drug partnership areas, plus written 
material from a further six. all were nominated by nta regional 
teams as helpful examples of partnerships running review 
processes for drug-related deaths. appendix one lists the areas 
reviewed. the research and drafting was carried out on behalf of 
the nta by mike Ward, an independent consultant. a steering 
group oversaw the process. its membership is set out in  
appendix two.
Acknowledgements: the nta thanks the partnership 
representatives and nta regional leads who took part in the 
research, and the members of the steering group. 
Terminology: ‘review process’ is used throughout as a convenient 
term to cover the range of procedures that exist, from confidential 
inquiries based on statistical data analysis alone, to drug-death 
reviews that involve elements of evidence and investigation.
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1. Introduction
the numbers of drug related deaths in England grew steadily up 
until 2001, as the heroin epidemic that started in the 1980s took 
its toll of injecting drug users. since then, the number of deaths 
reduced before a slight rise in recent years, although the latest 
figures from the Office for national statistics show a slight decline. 
Before publishing the 2009 figures, the Ons reviewed its codes 
for these deaths, resulting in significantly revised figures for 2007 
and 2008. these figures show us that even though drug related 
deaths haven’t continued at the same pre-2001 upward rate, the 
number of deaths is still too high [fig 1].
any drug-related death is a tragedy, and everyone agrees more 
needs to be done. the fastest rise in recent years has been among 
older, male heroin users. this group is increasingly vulnerable to 
the adverse effects of risky drug-taking behaviours. Prolonged 
heroin use causes chronic physical and psychological problems. 
it is not surprising, therefore, that as entrenched users get older 
they become more susceptible to infectious diseases such as 
hiv and hepatitis, collapsed veins and abscesses, liver or kidney 
disease, and pulmonary complications including the various types 
of pneumonia that result from depressing effects of heroin on the 
respiratory system. alongside these risks, heroin use over a long 
period of time increases the risk of drug-related death.
 
a review process can also provide an insight into local treatment 
practice, which may drive further improvements in that practice.
a range of agencies, from the police to treatment providers, are 
now working to reduce the number of drug-related deaths. review 
processes can make a vital contribution to this concerted effort.
for East riding Drug and alcohol action team, the benefits of a 
review process have been evident:
“The review process makes people more mindful of the risks and 
consequences for their clients. It improves practice, the learning 
points are taken to heart and it is safeguarding clients.”
more partnerships adopted review processes after the 2003 
publication of the Department of health’s Guidance for drug 
action teams on developing local confidential inquiries into drug 
related deaths. however, there are still areas that have no process 
or have one that could be revitalised.   
this document is a direct successor to the 2003 guidance and 
aims to replace it and enhance the advice offered to partnerships.
2. What is a review process?
“The aim is to prevent and reduce drug-related deaths. If you are 
not doing that, it is a waste of time.” (cornwall) 
a robust review process can help partnerships learn more about 
the events leading up to a drug-related death and take suitable 
measures that might prevent them from happening again. 
the review processes in local areas draw from the two main 
approaches found in the field: 
• confidential inquiries based on statistical data analysis
• drug-death reviews involving specific evidence-gathering and  
 investigation.
The confidential data inquiry: this focuses on gathering and 
analysing statistical data. it attempts to establish an accurate 
number of drug-related deaths and, from the available data 
sources, to analyse reliable information about their causes, 
changes in trends and the emergence of relevant new drugs or 
new ways of using drugs locally.
The drug-death review: this is a more investigative process. 
it involves receipt of reports on individual cases and an analysis 
of the narratives found. it attempts to identify ways to improve 
services, remedy system failures, develop opportunities for 
shared learning, and challenge and change practices through 
interpretation of the details of individual cases and groups of 
cases. 
most review processes contain elements of both these 
approaches. Drug-death reviews require more detailed 
information gathering and robust information sharing, whereas 
confidential data inquiries require expertise in statistical methods. 
the final structure of any review process will reflect the degree 
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to which it favours one or other of these procedures. therefore 
partnerships looking to develop or revamp a review process may 
want to consider what procedures will best help them achieve 
their aims before devising an appropriate system.
3. How to build a review process – a summary  
When developing a review process, partnerships may find it useful 
to ask themselves the following series of questions and to consider 
the issues that each individual question raises. this summary brings 
together the key points emerging from the research conducted 
among partnerships with working review processes. 
full details on each point can be found in the next section of 
this document, along with quotes and cases studies from the 
partnerships involved in the review. 
 
What is the purpose of the review process?
• some partnerships take a quantitative, confidential inquiry  
 approach that seeks to obtain a robust set of statistics
• Others adopt a more qualitative procedure that explores aspects  
 of service practice and delivery before a drug-related death
• most review processes take elements of both approaches. 
What defines a drug-related death?
• a definition is essential. most areas use the Office for national  
 statistics definition: A death where the underlying cause is  
 poisoning, drug abuse or drug dependence and where any of  
 the substances controlled under the Misuse of Drugs Act (1971)  
 are used
• some partnerships use a local definition that includes a wider  
 range of causes, such as volatile substance abuse or drug- 
 related homicides
• the actual cases that go to review may be only those that offer  
 the best opportunities for learning 
• most deaths reviewed are acute cases, usually overdoses, where  
 the cause and effect is easier to link than those involving  
 long-term physical decline 
• acute deaths also involve more agencies, such as the police,  
 and provide more data
• another option is to review non-fatal overdoses, though most  
 partnerships choose not to.  
Who leads the review process locally and who are they 
responsible to?
• a lead officer for reviewing drug-related deaths is a common  
 feature and can ensure consistent focus, though one lead’s  
 experience may vary from another’s depending on their  
 professional background
• the officer often analyses data and drafts reports. this   
 approach is simple, but offers limited expertise. can a   
 consultant psychiatrist, for example, clearly scrutinise the  
 way police handled the scene of death? can a police officer  
 meaningfully scrutinise the clinical decisions of a psychiatrist?
• is the overseeing group in a position to identify and analyse  
 such matters?
• most partnerships have a drug-related death group or a harm  
 reduction group that sits within the partnership, Pct or   
 community safety framework. these groups are typically chaired  
 by joint commissioning managers, public health directors,  
 partnership clinical governance leads or Pct medical directors
• good practice suggests a management framework is needed,  
 but what works well in one area may not work well in another. 
Which agencies are engaged in the review process?
• review processes may involve a wide range of agencies and  
 individuals, who either provide information or work on steering  
 groups 
• larger groups offer better insight and wider dissemination of  
 findings, but also pose more challenges when it comes to  
 sharing information 
• the sort of groups and individuals who have been involved  
 include service users, children’s services, drug treatment  
 providers, police, probation, prisons and mental health services. 
Have information-sharing and confidentiality issues been 
addressed? 
• Every review process needs a procedure for sharing information  
 on drug-related deaths. however, different agencies may have  
 different interpretations of the law on what can be shared, 
 when and with whom. 
• securing the next of kin’s agreement is often a good way to  
 avoid problems
• Other ways include an information-sharing protocol between  
 agencies; taking information primarily from coroners’ files;  
 asking the coroner’s office to request information from nhs  
 agencies
• it is important to consult nhs caldicott guardians when setting  
 up a review process. 
Are links being developed with neighbouring areas?
• some partnerships run a joint review process, others prefer to  
 work alone 
• Working jointly can mean more deaths to review, better  
 opportunities for learning, wider expert opinion and possible  
 economies of scale 
• some partnerships perceive drawbacks to joint processes,  
 feeling the solitary approach better suits the large urban or  
 county areas they cover, that their drug-related problems are  
 unique, and that it eases information sharing.
Has the coroner been engaged?
• involving the local coroner can greatly enhance a review process 
• local coroners tend to support review processes in principle,  
 and usually offer at least some access to records
• Day to day contact is often via the coroner’s officers
• some coroners are unwilling to engage. in this case,   
 partnerships will need to consider other ways of identifying  
 deaths and obtaining information about them.
Are other agencies notifying deaths? 
• Other agencies can notify deaths instead of (or as well as) the  
 coroner. the most common alternative sources are the police  
 and drug services 
• some partnerships have a specific form for reports of drug  
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 deaths. Others receive direct calls or emails 
• Other potential sources are a&E units, the ambulance service  
 and even local newspapers, though reliability is not guaranteed  
 and additional checking may be needed
• another possible approach is to require reporting as part of  
 service provider contracts.
How does the review process relate to other, similar 
processes?  
• mental health trusts and other bodies have processes for  
 investigating critical incidents involving violence or self-harm 
• the most common are serious untoward incident (sUi)   
 processes. sUis review drug-related deaths within trusts and can 
 identify drug-related aspects in other incidents 
• most partnerships try to avoid duplicating these processes, but  
 look to learn lessons from them 
• Drug-death review groups often receive anonymised   
 recommendations from relevant sUi reports. 
How does the timing of the review process relate to the 
coroner’s verdict?
• most partnerships wait until after the coroner’s verdict before  
 launching a review. this ensures they review only confirmed  
 drug-related deaths 
• some areas start earlier, usually when rapid action is needed to  
 change the way things work 
• a problem with waiting for a coroner’s verdict is the time lag:  
 more than five months in some cases.
Is it a ‘no blame’ or ‘fair blame’ system? 
• the review process may uncover poor practice by a member of  
 staff, but all partnerships describe their systems as ‘no fault’ or  
 ‘no blame’ 
• in reality, most partnerships recognise reviews might identify  
 negligence, so have a procedure for managing such situations 
• this makes their systems more akin to those usually described  
 as ‘fair blame’, which is a more realistic approach
• incidents would generally be notified to appropriate managers  
 within the relevant agency.
Are face to face interviews or written data-gathering 
methods used?
• most review processes are based on written material, including  
 completed forms, inquest documents, files and internal reports 
• Only a few systems interview staff face to face about the  
 deceased.
Are people involved in investigative processes 
appropriately skilled?
• no specific or standardised training exists for those undertaking  
 review processes, although all of the leads interviewed are  
 experienced in conducting investigations and this would seem  
 to be a minimum requirement
• lead officers have a range of skills, including conducting sUis,  
 root-cause analysis and qualitative research methods 
• the lead needs a broad understanding of the effects of drugs  
 and the principles of harm reduction, or the overseeing group  
 should provide extra support
• leads also need to be able to work effectively with a wide  
 range of people, including professionals and families.  
Are relatives/carers involved?
• relatives and carers of the deceased may be involved in  
 investigations which contribute to the review process, but none  
 of the partnerships interviewed currently involve relatives or  
 carers of deceased drug users in the review process itself 
• involving relatives and carers can add an important key   
 perspective to the process and may be increasingly expected of  
 an nhs which has committed to working in partnership with  
 families and carers (nhs constitution, 2010). it may also ease  
 information sharing if the next of kin release notes
• the process may be emotionally hard for families, making it  
 difficult to maintain a ‘fair blame’ approach and causing  
 services to resist sharing information. 
How are the findings to be reported and disseminated?
• Partnerships keep a record of findings and recommendations,  
 ranging from the minutes of the meetings to public reports.  
 some publish an annual report, others send details to the  
 coroner 
• internally, the findings tend to be disseminated by agencies,  
 along with members of the drug-related death or harm  
 reduction groups.
How are proposed actions reviewed?
• Partnerships have a variety of structures for monitoring review  
 processes and the action that emerges from them. Often the  
 lead officer reports to the steering group on progress 
• recommended actions from a review process can be written  
 into treatment plans.
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1. How to build a review process
 
What definition of drug-related deaths is used?
a definition of the type of death to be reviewed is essential. most 
areas interviewed used the Office for national statistics definition: 
 
A death where the underlying cause is poisoning, drug abuse or 
drug dependence and where any of the substances controlled 
under the Misuse of Drugs Act (1971) are involved. 
however, some partnerships use a local definition, which gives 
them the opportunity to include a wider range of deaths, such as 
volatile substance abuse cases or deaths in cars while intoxicated. 
Birmingham reviewed the case of a man who was stabbed to 
death but was found surrounded by drug paraphernalia.
the definition used to identify drug-related deaths may differ to 
that used to decide what deaths go to a review. local partnerships 
may well not review all deaths, but rather those that offer the 
most (or specific) learning opportunities.
in general, the deaths reviewed tend to be acute incidents, usually 
overdose. this is because the links between cause and effect are 
easier to trace in an acute incident than in a death that involves 
several years of physical decline. acute deaths are also likely to 
require the resources of more agencies, such as the police or 
ambulance service. nottingham and nottinghamshire also review 
deaths from bacterial infections, although they can experience 
difficulty in obtaining this information. 
most partnerships were not looking at ‘near-miss’ non-fatal 
overdoses within the drug death review process but this is an 
option that can be considered. three partnerships reported action 
on this, but none within the drug death review system itself.
East sussex: “We have just introduced a programme to look at 
near misses. We have a form with the ambulance service. It has 
just started and we have had no cases so far. The form will go to 
a treatment service for them to make contact with the person 
who overdosed… we will also gather data on the number of near 
misses and the number who then enter treatment services.” 
East riding: “We have just had a discussion about near misses 
with the accident and emergency unit. At the moment we don’t 
receive that sort of information because of the lack of a data 
sharing agreement, the trust is now considering whether to 
review this. A substance misuse liaison nurse at the hospital is 
now in post to pick these up and make contact.” 
 
Who leads the process locally and who are they  
responsible to?
cornwall and leeds have each appointed a dedicated drug-related 
death investigation officer. having a dedicated post ensures a 
consistent focus on the issue. Beyond that, no evidence emerged 
about where the leadership was best placed. 
the partnerships interviewed had all identified a lead officer for 
the review process. however, actual practice varied greatly. local 
leads included:
• consultant psychiatrist 
• community safety officer
• service manager 
• Joint commissioning manager
• Partnership clinical governance lead 
• Partnership coordinator
• Partnership harm reduction lead
• Public health specialist. 
in many systems the lead officer is the main person analysing 
data and drafting reports. this is a simple system but has the 
disadvantage that only one area of expertise is brought to 
bear on the information. Will a consultant psychiatrist identify 
issues about how the police handled the scene of death? Will 
a community safety officer pick up connections between the 
death and other health problems suffered by the deceased? if a 
single lead is to review the data, it is important to ensure those 
overseeing the process have the opportunity and expertise to 
identify these links.
the leads will be responsible to a particular group. in most of the 
partnerships reviewed this is either a specific drug-death group 
or a harm-reduction group. these groups are chaired by joint 
commissioning managers, directors of public health, partnership 
clinical governance leads or medical directors of the Pcts, and 
they tend to sit within a partnership, Pct or community safety 
framework.
it is impossible to say which of these approaches is the most 
effective. however, effective practice requires some form of 
management framework, i.e. oversight of the process and links 
into other agencies or other parts of an organisation. 
What agencies are engaged in the review process?
a wide range of agencies and individuals may be involved in 
reviews, either as sources of information or members of steering 
groups. the list below summarises the range of participants 
identified as group members around the country. larger groups 
offer the benefit of better oversight and wider dissemination 
of findings. however, one point to note is that in larger groups 
information-sharing may become more challenging.
• service users
• children’s services
• Drug treatment providers
• Public health
• Police
• Probation
• ambulance service
• Prisons
• Pharmacy
• social care
• Drug interventions Programme
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• mental health services
• hostels and other homelessness services
• hepatitis c/blood-borne virus nurses
• sexual health project
• Primary care 
• fire service
• Young people’s substance misuse service
• specialist substance misuse midwife
• health Protection agency.
leeds reported having advisory members who did not attend the 
group meetings but who could be asked to inform the process. 
these comprised the coroner and a representative each from 
the nta and the accident and emergency unit. it was reported 
that the coroner’s membership added status to the group and 
encouraged other people to join.
Have information sharing/confidentiality issues been 
addressed?
information sharing arrangements will have to be in place 
between all parties to the review. this has presented problems in 
a number of areas because different agencies have interpreted 
the law around information sharing in different ways.  some nhs 
trusts have refused to share information without permission from 
the next of kin. Partnerships identified the following concerns:
“This issue has rumbled on and the review leads have had to leave 
the acute trusts aside and are simply doing it within the existing 
organisations. The mental health trust has signed up. We are now 
going out to secure agreement with individual organisations. We 
have had information from GPs in the past but it has not been 
consistent.”
“The main problem has been how to send out the information 
collection proforma. But we came to an agreement with the PCT 
clinical governance lead about how to share it.” 
“In some NHS services the Caldicott Guardians have been 
extremely unwilling to share information unless it was at the 
request of the family or the coroner.”
“We have had problems with the mental health trust who feel 
that the SUI covers this responsibility. We can get reports via the 
coroner but are not getting direct cooperation.”
“One GP invoiced us £45 for supplying information.”
“We cannot access data from GPs. However, we do receive 
information from the hospital.”
securing the agreement of the next of kin is the surest way to 
avoid problems (see ‘are relatives/carers involved?’ on page 9). 
Partnerships identified various other means to ease the process:
• an information sharing protocol between agencies, e.g.  
 cornwall 
• gathering information from coroners’ files, e.g. nottingham  
 and nottinghamshire
• the coroner’s officer sending out the information requests to  
 nhs agencies on behalf of the partnership, e.g. East riding.
the legal framework for sharing, and even transmitting, 
information about a deceased person is complex and partnerships 
will need to consult with all partners to establish the boundaries 
for the process. it will be important to consult caldicott guardians 
within the nhs when establishing review processes.
Are links being developed with neighbouring areas?
the research identified areas where multiple partnerships were 
working together on a joint review system. these included the 
south West Peninsula and teesside. Other systems worked across 
two neighbouring partnerships, e.g. leeds and Wakefield, who 
have different systems but the same investigator, and nottingham 
and nottinghamshire. 
Working with other areas has the benefit of providing a larger 
sample of deaths to review. this can increase the potential 
learning, and introduce economies of scale and a greater range of 
expert opinion to the process. these benefits may be particularly 
important for smaller partnerships. Other motivations are that the 
same coroner covers adjoining areas or that treatment services are 
shared.
however, single partnership processes operated in the majority of 
areas reviewed. this was because disadvantages were perceived 
in joint processes. in some cases the unitary approach was felt 
to be appropriate because the partnerships covered large urban 
or county areas. in other places it was felt local problems were 
unique or different to neighbouring areas. indeed one partnership 
felt having its own system worked better than a previous shared 
system because partners were more willing to share information.
Has the coroner been engaged?
the majority of partnerships reviewed had engagement with 
their local coroner, although none were actually involved in the 
detailed process. in general the relationship focused on support 
for the principle of the review and varying degrees of access to the 
coroner’s records.
those partnerships with involvement stressed how much this 
eased the process:
East sussex: “We have full access to the coroner’s data. We receive 
a notification and inquest report from the coroner and have 
unrestricted access to the files.” 
nottingham and nottinghamshire: “The coroner was invited to sit 
on the group but decided because of time constraints he could 
not do it. He has supported the process and we have free access 
to the files. The coroner does not alert the partnership to the 
deaths: they are generally identified by primary reporting from the 
police and the provider agencies. However, the partnership lead 
goes to the coroner’s office on a quarterly basis and checks the 
day book to ensure we have not missed any deaths.”
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East riding: “The coroner’s involvement has made the process a 
great deal easier. In some NHS services the Caldicott Guardians 
were unwilling to share information unless it was at the request 
of the family or the coroner. At the beginning we had to contact 
families. This was not popular, but now the coroner’s officer sends 
out the information request to NHS agencies and this smoothens 
the partnership.” 
leeds: “The coroner is engaged and fully supports the process… 
he gave unfettered access to the files.”  
Brighton: “The coroner keeps her own tallies as she does for all 
sorts of other deaths. The drug death review lead goes to the 
coroner’s office about once every couple of months.” 
cornwall: “The drug death review lead is invited to every drug-
related inquest. The coroner is also asking the lead to come to 
some alcohol related deaths. Protocols are in place to cover this.”
in many cases, partnerships had day-to-day contact with coroner’s 
officers, who can be an important link in the process.
however, some areas had no contact with the coroner. no 
mechanism exists to compel coroners to cooperate. they have the 
right not to participate in review processes. files from inquests are 
the property of the coroner and they control how they manage 
this information. if a coroner is unwilling to share information, 
partnerships will need to consider other means of identifying 
deaths and acquiring information on the deceased.
Are other agencies notifying deaths?
Other agencies can also notify deaths. in some cases, this is 
instead of coroner notification; in others, alternative notifications 
work alongside the coroner’s information. 
the main other agencies that have been reported as notifying 
deaths in some areas are the police and the local drugs services. 
some partnerships have a specific form for reporting. in others, 
these agencies have been expected to email or call the lead 
officer. in Blackpool, the police notify the lead via a regularly 
updated spreadsheet or monthly report. 
One partnership had attempted to secure reporting from prisons, 
the accident and emergency unit, and the ambulance service, 
but was receiving little from these sources. another area used the 
local newspaper as an additional source of information.
no examples were found of a requirement to report being 
included as part of service provider contracts. While this is an 
approach that could be considered, it would be likely to require 
consideration of suitability by the local caldicott guardian. 
as part of the operation of their local review process the local 
drugs partnership may seek agreement from all partners in the 
process that they will share news of a death as part of appropriate 
data sharing arrangements. East riding provides an example of 
such an agreement.
How does this process link to, and avoid duplication with, 
other review processes?
a number of acts of violence or self-harm are subject to inquiry 
processes, which include:
• Part 8 child death reviews
• internal serious untoward incident (or critical incident)   
 processes in mental health services (covering homicides,  
 suicides, violent acts and serious self harm)
• independent mental health homicide inquiries
• inquiries into homicides related to domestic violence.
Where possible, it would be advisable for partnerships to:
• avoid duplication with these processes
• seek to learn relevant lessons from them. 
Of these the most relevant, because they are most frequent, are 
serious Untoward incident (sUi) or critical incident processes 
within local provider services based in mental health trusts. it is 
reasonable to expect that sUis will review drug-related deaths 
occurring within trusts and have the expertise to identify drug-
related aspects in other incidents. 
in East sussex the link is secured because the lead for the review 
process is a local consultant psychiatrist who is automatically 
involved in sUis.
in nottinghamshire, if a drug user dies, while under the care of 
drug services provided by the local mental health trust or Pct, 
the confidential inquiry review group (cirg) researchers will 
use the findings of the trusts’ own serious Untoward incident 
investigations, to avoid duplication of work.  
Plymouth has a Daat sUi policy that all providers are expected to 
adhere to, that is co-owned with the Pct. in a recent joint review 
with mental health services, the Daat investigated the substance 
misuse elements, and the mental health services reviewed the 
mental health elements to provide a joint report of findings and 
recommendations. the Daat can lead the sUi process if the 
deceased was in drug treatment.
in cornwall, the Daat officer investigates every single drug-
related death and the subsequent report is considered as part of 
the sUi process. 
at the least, it is reasonable to expect that drug-death review 
groups will receive anonymised recommendations from relevant 
sUi reports. 
the other inquiry processes mentioned above are far less frequent 
than sUis but partnerships will want to be aware of the possibility 
of learning from such inquiries. 
 
How does the timing of the process relate to the coroner’s 
verdict?
a small but significant issue is how the timing of the review 
process relates to the coroner’s verdict on the case.
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the majority of partnerships contacted wait until after the 
coroner’s verdict before launching a review. the advantage of this 
is that it avoids reviewing deaths that the coroner concludes are 
not drug-related. 
Blackpool: “If it was done pre-inquest at least a third would not be 
our cases because the coroner comes up with a different verdict.”
however, some areas, e.g. leeds, lincolnshire and Birmingham, 
see an advantage in an earlier or ‘hot’ review process. in some 
cases it may be felt there is a need for rapid action to change 
the way things work.  the leeds process delivers findings within 
10 weeks of the death, which is the time it takes for toxicology 
reports to be available. East riding can call a meeting within a 
fortnight of a death being reported. 
a particular problem with waiting for the coroner’s verdict is the 
time lag involved. Partnerships interviewed reported waits of four 
to five months or longer.
in cornwall the partnership lead officer is more closely involved 
in the inquest process itself and can make suggestions to the 
coroner about a case.
Is it a ‘no blame’/‘fair blame’ system?
Every partnership contacted described its system as a ‘no fault’ 
or ‘no blame’ system. Birmingham commented that this “helped 
to get people on board in the first place.” cornwall, Devon and 
Plymouth said: “We emphasise training needs rather than blame.”
in absolute terms these cannot be ‘no blame’ systems. the 
guidance document: Clinical governance in drug treatment: A 
good practice guide for providers and commissioners (nta 2009) 
talks about this as ‘fair blame’:
“It is an important principle of effective clinical governance that 
encouraging an appropriate culture of openness underpins the 
approach to dealing with untoward incidents. This is sometimes 
referred to as a ‘fair blame’ culture. While this does not remove or 
replace appropriate accountability for poor practice or negligence, 
it is an approach that anticipates that errors are inevitable in 
human practice and in organisations.” 
in reality, most partnerships recognised that reviews might identify 
negligence, though only one had identified an issue that came 
close to negligence. so a process needs to be in place for managing 
such situations. in general it was reported that incidents would be 
notified to appropriate managers within the relevant agency.
Are face to face interviews or written data-gathering 
methods used?
the majority of review processes do not gather data through 
interviews with workers. most are based on written materials: 
completed forms, copies of materials from the inquest, file 
material or reports from internal inquiries. two systems were 
identified (leeds and cornwall) where staff, such as drug service 
workers, were interviewed face to face about the deceased.
Are people involved in investigative processes 
appropriately skilled? 
the focus here is on the skills of the individual leading the review 
process but,as one partnership made clear, the whole review 
group contributes to the investigation so the combination of 
required skills may be found in different individuals.  
no specific or standard training exists for undertaking drug-related 
death reviews. in the partnerships reviewed the leads had a 
range of backgrounds and training: two leads were former police 
officers, one lead had training in sUis, and two had training in 
root-cause analysis. Other training included qualitative research 
methods.  
all of the leads interviewed were experienced in conducting 
investigations and this would seem to be a minimum requirement. 
some groups had considered the competencies required of their 
leads and identified training needs which they planned to address. 
it will be important to ensure those leading the process have 
either a broad understanding of the response to drugs as well as 
the principles of harm reduction, or that the group overseeing the 
process can provide additional support.
leads also need to be able to work effectively and sensitively with 
a wide range of people, including professionals from a range of 
different disciplines and members of the public, perhaps including 
the families of the deceased. the police, for example, receive 
training in how to handle recently bereaved people and deal with 
them sensitively.   
 
Are relatives/carers involved?
relatives and carers of the deceased may be involved in 
investigations which contribute to the review process, such 
as coroners’ inquiries or sUis, but none of the partnerships 
interviewed involved relatives and carers in the review process 
itself. however, in Derbyshire the police recommend a local service 
for the family of drug users as a support to the relatives of the 
deceased. in those systems where the lead attends the inquest, 
such as cornwall and the East riding, family members may be 
encountered although they are not subsequently involved in 
reviews.
 
involving relatives and carers is complex, and it is recommended 
that partnerships carefully consider how they approach this issue. 
involving relatives and carers may add an important perspective 
to the process and may be increasingly expected of an nhs which 
has committed to working in partnership with families and carers 
(nhs constitution, 2010). it may also make information sharing far 
easier because next of kin can give permission for the release of 
notes.
however, under these circumstances it may be harder to maintain 
the ‘fair blame’ approach and services may be more resistant to 
sharing information. moreover, the process may be emotionally 
difficult for family members.
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How are the findings to be reported and disseminated?
Partnerships will want to keep some record of findings and 
recommendations. in the partnerships reviewed, records ranged 
from the minutes of the meeting to a public report. Brighton 
has been publishing an annual report for the past seven years. 
nottingham and nottinghamshire produce an annual report, 
which is sent to local commissioning bodies and distributed to 
relevant individuals and organisations. 
Dissemination tends to be either via the members of the drug-
related death or harm-reduction group or via agencies. East 
sussex presents the report to agencies and their staff and then it 
goes to the coroner. Derbyshire expects individual agencies to take 
responsibility for feeding back learning to their own organisation. 
in Brighton, data also feeds in to the needs assessment.
How are proposed actions reviewed?
a variety of monitoring structures were identified. Often the lead 
officer reports to the steering group on progress. in Birmingham 
the lead reports back to the drug-death group. in East sussex, the 
joint commissioning manager takes the recommendations and 
works on them. they can be written into the treatment plan. local 
leads also look back at the inquiries to see what has happened.
2. Processes in action 
 
Each partnership consulted had developed review processes in 
different ways. aims, methodologies and outputs all varied. this 
document is not promoting one system as better than another. 
this section simply highlights examples of how partnerships 
have put these systems into operation. East sussex offers a 
comprehensive process that addresses the majority of the issues 
raised above. Derbyshire is included as an example because it uses 
internal inquiry processes to provide the drug-related death group 
with information for its reviews. lincolnshire runs an example of a 
‘hot’ review process: the reviews take place within a fortnight of 
the death. 
East Sussex
East sussex’s process has two leads (a psychiatrist and a 
community safety officer) that are responsible to a specific 
drug-related death steering group, which in turn links to the 
local Daat. notification of deaths comes from the coroner 
who supports the process. 
after the coroner has notified the leads of five or six deaths 
an appointment is made to visit the coroner’s offices. this 
happens quarterly to half yearly. a standard form is used 
to gather quantitative and qualitative information from the 
coroner’s records.  
the leads look to see if the cases fit the local definition of 
a drug-related death and then seek further information. 
a standard letter is sent to the deceased’s gP seeking 
information. they also look at health records and, if 
appropriate, contact prisons to gather further information. 
the police have a form to submit information for each 
suspected death. the leads also check if any children are 
involved and then contact children’s services.  
the leads review the evidence and write a report on lessons 
learned and recommendations. the draft report goes to 
the drug-death group for discussion. this final report is sent 
to the Daat board, to local services and the coroner. the 
joint commissioning manager uses the recommendations in 
planning. 
the drug-related death steering group looks back 
at past inquiries to see what has happened on any 
recommendations.
Derbyshire
Derbyshire’s process is led by the Daat clinical governance 
lead who is responsible to a drug-death group, which in turn 
is responsible to the joint commissioning group (Jcg). 
notifications come to the Daat via the police on a specifically 
designed form.
the drug-death group meets bimonthly. Before, members 
receive the proforma on each death, giving the opportunity 
to check whether their agency knew the deceased and 
whether they have any further information. services share 
information and any initial findings at the meeting. however, 
it is expected that a service’s own sUi process will then 
take over and the group will wait for that to be completed 
and report back. recommendations come from the service 
investigations or to a lesser extent via the discussions in the 
group.
Provider summaries are incorporated in reports for the 
Daat board, and the information on the lessons learned is 
disseminated to clinical groups as appropriate. Providers also 
feed back learning to their own organisation. 
Lincolnshire
in its most recent review, the lead was notified of the 
death by a local drugs agency within 24 hours. agencies 
are required to notify the Daat. the next week the Daat 
hosted a two-hour meeting to look at what had happened. 
the attendees were determined by who was involved with 
the client, based on the provider agency’s information.  the 
outputs were the minutes of the meeting. these go to the 
drug reference group and to the Jcg. the Daat expect 
to have a performance-assurance review group with the 
provider to pick up on actions.
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3. The benefits 
those partnerships running review processes could all identify real 
benefits:  
 
cornwall: “It has highlighted various gaps and problems in the 
network and system of services. There is also recognition of good 
practice.” 
Brighton: “Drug-related death rates have come down. Intelligence 
has been improved and we can identify trends or hotspots.”
Plymouth: “The review process has developed a joint approach 
and created collaborative working.” 
leeds: “The review process has contributed to an overall reduction 
in deaths… It has also raised significant interest and attention.”
the examples in the previous section highlight there is no 
single right way of running a review process. the purpose of 
this document is to encourage each partnership to choose an 
approach that best suits their local needs. the biggest loss would 
be not to have a process and to lose the vital information that can 
be gathered from drug-related deaths.
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AppenDix one: list of pArtnerships 
ConsulteD 
• Birmingham
• Blackpool
• Brighton
• cornwall
• Devon
• Derbyshire
• East riding
• East sussex
• leeds
• lincolnshire
• nottingham
• nottinghamshire
• Plymouth
• teesside
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AppenDix two: MeMbership of the steering 
group
 
• Dr alastair Boyd (medical officer, Department of health)
• Dr John Dunn (consultant psychiatrist and clinical team lead,   
   nta)
• mike flanagan (consultant nurse in addiction, surrey & Borders   
   Partnership nhs foundation trust)
• Dr linda harris (clinical director, primary care substance misuse,  
   Wakefield integrated substance misuse service) 
• michelle Judge (harm reduction officer, nta)
• hugo luck (national programme lead, policy, nta) (chair first  
   meeting)
• Emily makin (risk coordinator, turning Point)
• neil O’Byrne (drug-related death investigator, leeds &      
   Wakefield)  
• Beverley Oliver (regional manager, north East region, nta)
• si Parry (coordinator, m.O.r.P.h.)
• Dr mark Prunty (senior medical officer for substance misuse  
   policy, Department of health)
• Dr Penny schofield (clinical team gP, nta)
• steve taylor (programme manager, skills and practice   
   development team, nta) (chair)
• sue tutton (coordinator, m.O.r.P.h.)
• marion Walker (clinical team pharmacist, nta)
